Home > Insider Trading > Filing (0001144204-14-053100)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443723	T. James Gunton	C/O Cytosorbents Corporation 7 Deer Park Drive, Suite K Monmouth Junction NJ 08852		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-08-18	3,106,988	$0.00	3,106,988	No	4	C	Indirect	By Partnership
Common Stock	Disposition	2014-08-26	1,000,000	$0.24	2,106,988	No	4	S	Indirect	By Partnership
Common Stock	Disposition	2014-08-27	360,000	$0.24	1,746,988	No	4	S	Indirect	By Partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Partnership
No	4	S	Indirect	By Partnership
No	4	S	Indirect	By Partnership

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2014-08-18	1,125	$0.00	3,106,988	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
39,091			No	4	C	Indirect

Footnotes

Each share of Series B Preferred Stock has a stated value of $100.00, is convertible at the holder's option into that number of shares of Common Stock equal to the Series B stated value at a conversion price of $0.0362, and has no expiration date.
These securities are held directly by NJTC Investment Fund, LP, of which the Reporting Person is a partner. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or any other purpose.
The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $0.237 to $0.25.
The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $0.24 to $0.25.